Survival, Morbidity, and Quality of Life in Pulmonary Arterial Hypertension Patients: a Systematic Review of Outcomes Reported by Population-based Observational Studies

Overview

Journal Respir Res

Specialty Pulmonary Medicine

Date 2024 Oct 16

PMID 39415261

Authors

Stefan Reinders

Eva-Maria Didden

Rose Ong

Affiliations

Soon will be listed here.

Abstract

Background: Comprehensive summaries on real-world outcomes in pulmonary arterial hypertension (PAH)-a rare, incurable condition, are lacking. We conducted a systematic literature review to describe current survival, morbidity, and quality of life (QoL) outcomes in adult and pediatric PAH patients. We searched Medline and Embase electronic databases, clinicaltrials.gov, and encepp.eu entries, and grey literature to identify outcome estimates for right-heart catheterization-confirmed PAH patients from population-based observational studies (search date: 25 Nov 2021). Data were synthesized using a narrative approach and post-hoc subgroup meta-analyses were conducted to explore adult survival by region, disease severity, representativeness, and study period. The search yielded 7473 records. Following screening and full text review, 22 unique studies with 31 individual reports of outcomes were included. Studies were mostly national registries (n = 21), European (n = 13) and covering adults (n = 17); only six had systematic countrywide coverage of centers. Survival was the most frequently reported outcome (n = 22). Global adult 1-, 3-, and 5-year survival ranged from 85 to 99% (n = 15), 65 to 95% (n = 14), and 50 to 86% (n = 9), respectively. Subgroup meta-analysis showed that 1-, 3-, and 5-year survival in Europe was 90% (95% CI 86-94%; n = 8), 78% (95% CI 68-86%; n = 8), and 61% (95% CI 49-72%; n = 6), respectively; 1-year survival in North America was 88% (95% CI 83-93%; n = 3) and 3-year survival in Asia was 85% (95% CI 82-88%; n = 3). No difference in survival between regions was observed. Subgroup analysis suggested higher survival in patients with better baseline functional class; however, interpretation should be cautioned due to large subgroup heterogeneity and potential missingness of data.

Short Conclusion: This review describes current disease outcomes based on well-defined and representative PAH populations. There is an overall lack of follow-up data for morbidity and QoL outcomes; survival estimates for pediatric patients are scarce and may not be generalizable to the current treatment era, although publications from large pediatric registries became available after our search date. This study demonstrated a remaining unmet need world-wide to improve long-term prognosis in PAH in the current era.

References

Harikrishnan S, Sanjay G, Ashishkumar M, Menon J, Rajesh G, Kumar R . Pulmonary hypertension registry of Kerala, India (PRO-KERALA) - Clinical characteristics and practice patterns. Int J Cardiol. 2018; 265:212-217. DOI: 10.1016/j.ijcard.2018.02.036. View

Sitbon O, Vonk Noordegraaf A . Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience. Eur Respir Rev. 2017; 26(143). PMC: 9489058. DOI: 10.1183/16000617.0055-2016. View

Kylhammar D, Kjellstrom B, Hjalmarsson C, Jansson K, Nisell M, Soderberg S . A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension. Eur Heart J. 2017; 39(47):4175-4181. DOI: 10.1093/eurheartj/ehx257. View

Chen H, Taichman D, Doyle R . Health-related quality of life and patient-reported outcomes in pulmonary arterial hypertension. Proc Am Thorac Soc. 2008; 5(5):623-30. PMC: 2645237. DOI: 10.1513/pats.200802-020SK. View

Chung W, Park Y, Jeon C, Jung J, Ko K, Choi S . Baseline Characteristics of the Korean Registry of Pulmonary Arterial Hypertension. J Korean Med Sci. 2015; 30(10):1429-38. PMC: 4575931. DOI: 10.3346/jkms.2015.30.10.1429. View

Hoeper M, Pausch C, Grunig E, Staehler G, Huscher D, Pittrow D . Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry. Eur Respir J. 2021; 59(6). PMC: 9160392. DOI: 10.1183/13993003.02024-2021. View

Zelt J, Sugarman J, Weatherald J, Partridge A, Liang J, Swiston J . Mortality trends in pulmonary arterial hypertension in Canada: a temporal analysis of survival per ESC/ERS guideline era. Eur Respir J. 2021; 59(6). PMC: 9160389. DOI: 10.1183/13993003.01552-2021. View

Farber H, Miller D, Poms A, Badesch D, Frost A, Muros-Le Rouzic E . Five-Year outcomes of patients enrolled in the REVEAL Registry. Chest. 2015; 148(4):1043-54. DOI: 10.1378/chest.15-0300. View

Hasan B, Hansmann G, Budts W, Heath A, Hoodbhoy Z, Jing Z . Challenges and Special Aspects of Pulmonary Hypertension in Middle- to Low-Income Regions: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020; 75(19):2463-2477. DOI: 10.1016/j.jacc.2020.03.047. View

10.

Appenzeller P, Lichtblau M, Berlier C, Aubert J, Azzola A, Fellrath J . Disease characteristics and clinical outcome over two decades from the Swiss pulmonary hypertension registry. Pulm Circ. 2022; 12(1):e12001. PMC: 9052988. DOI: 10.1002/pul2.12001. View

11.

DuBrock H, Reddy Y, Durst L, Schroeder D, Park G, Cajigas H . The feasibility and value of assessing patient-reported outcomes in pulmonary arterial hypertension. Pulm Circ. 2022; 12(4):e12143. PMC: 9575699. DOI: 10.1002/pul2.12143. View

12.

Radegran G, Kjellstrom B, Ekmehag B, Larsen F, Rundqvist B, Blomquist S . Characteristics and survival of adult Swedish PAH and CTEPH patients 2000-2014. Scand Cardiovasc J. 2016; 50(4):243-50. DOI: 10.1080/14017431.2016.1185532. View

13.

Kozu K, Sugimura K, Ito M, Hirata K, Node K, Miyamoto T . Current status of long-term prognosis among all subtypes of pulmonary hypertension in Japan. Int J Cardiol. 2019; 300:228-235. DOI: 10.1016/j.ijcard.2019.11.139. View

14.

Thenappan T, Shah S, Rich S, Gomberg-Maitland M . A USA-based registry for pulmonary arterial hypertension: 1982-2006. Eur Respir J. 2007; 30(6):1103-10. DOI: 10.1183/09031936.00042107. View

15.

Chang K, Duval S, Badesch D, Bull T, Chakinala M, De Marco T . Mortality in Pulmonary Arterial Hypertension in the Modern Era: Early Insights From the Pulmonary Hypertension Association Registry. J Am Heart Assoc. 2022; 11(9):e024969. PMC: 9238604. DOI: 10.1161/JAHA.121.024969. View

16.

Gidwani S, Nair A . The burden of pulmonary hypertension in resource-limited settings. Glob Heart. 2015; 9(3):297-310. DOI: 10.1016/j.gheart.2014.08.007. View

17.

Favoccia C, Kempny A, Yorke J, Armstrong I, Price L, McCabe C . EmPHasis-10 score for the assessment of quality of life in various types of pulmonary hypertension and its relation to outcome. Eur J Prev Cardiol. 2018; 26(12):1338-1340. DOI: 10.1177/2047487318819161. View

18.

Sitbon O, Channick R, Chin K, Frey A, Gaine S, Galie N . Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2015; 373(26):2522-33. DOI: 10.1056/NEJMoa1503184. View

19.

Swinnen K, Quarck R, Godinas L, Belge C, Delcroix M . Learning from registries in pulmonary arterial hypertension: pitfalls and recommendations. Eur Respir Rev. 2019; 28(154). PMC: 9488628. DOI: 10.1183/16000617.0050-2019. View

20.

Hoeper M, Pausch C, Olsson K, Huscher D, Pittrow D, Grunig E . COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension. Eur Respir J. 2021; 60(1). PMC: 9260123. DOI: 10.1183/13993003.02311-2021. View